Journals / Eurasian Journal of Pulmonology / 2021 / Cilt: 23 - Sayı: 3

Analysis of emergency department admissions of a chest diseases hospital during the early period of SARS-CoV-2 outbreak

Pages
185–190
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSIONS: The presence of fever and GGO with bilateral involvement on HRCT could be used for the early detection and triage of suspected patients in ED.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:BACKGROUND AND AIM: COVID‑19 shares similarities with lung diseases and causie difficulties in the management.
📊
Key Findings & Data:MATERIALS AND METHODS: ED admissions from March 11, 2020, to May 11, 2020 were retrospectively evaluated.
💡
Conclusion & Impact:CONCLUSIONS: The presence of fever and GGO with bilateral involvement on HRCT could be used for the early detection and triage of suspected patients in ED.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

BACKGROUND AND AIM: COVID‑19 shares similarities with lung diseases and causie difficulties in the management. The aim of this study is to describe demographic, clinical, laboratory, and radiological characteristics of patients who admitted to the emergency department (ED) of a chest diseases hospital and how we managed these patients. MATERIALS AND METHODS: ED admissions from March 11, 2020, to May 11, 2020 were retrospectively evaluated. Patients were divided into two groups as probable COVID-19 (P-COVID-19) and non-COVID-19. The data were analyzed and compared. RESULTS: A total of 223 patients, of which 31.8% were P-COVID-19 and 68.2% were non-COVID-19, were included. The mean age was 49.14 ± 18.05 years in P-COVID-19 group and 59.17 ± 17.32 years in non-COVID-19 group (P < 0.001). The most common symptoms in all patients were dyspnea (26.5%) and cough (21.1%). In P-COVID-19 group, cough, dyspnea, and fever were the most common symptoms, and the presence of fever was statistically significantly higher (P = 0.03). Increased C-reactive protein, sedimentation, and D-dimer levels were observed in 61.5%, 70.9%, and 52.6% of patients, respectively. Laboratory findings showed no significant differences between two groups. All patients underwent chest X‑ray examination and 42.6% of them had pathological findings. 56.3% of P‑COVID‑19 patients had normal chest X‑rays. Bilateral involvement on HRCT was more frequent in P-COVID-19 group than non-COVID-19 group (47.8% vs. 36.7%, P < 0.001). The presence of ground‑glass opacity (GGO) was statistically significantly higher in P-COVID-19 group (P < 0.001). CONCLUSIONS: The presence of fever and GGO with bilateral involvement on HRCT could be used for the early detection and triage of suspected patients in ED.

🔖

Cite This Article

SÖYLER, Y., UĞURMAN, F. (2022). Analysis of emergency department admissions of a chest diseases hospital during the early period of SARS-CoV-2 outbreak. Eurasian Journal of Pulmonology, Cilt: 23 - Sayı: 3, 185–190. https://ajindex.com/articles/509549

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Valencia DN. Brief review on COVID‑19: The 2020 pandemic caused by SARS‑CoV2. Cureus 2020;12:e7386
  2. World Health Organization. Naming the Coronavirus Disease (COVID‑19) and the Virus that Causes It. Available from: https://www.who.int/emergencies/diseases/novelcoronavirus-2019/technical-guidance/naming-the-coronavirusdisease-(covid‑2019)-and-the-virus‑that‑causes‑it. [Last accessed on 2020 Jul 19]
  3. World Health Organization. WHO Director‑General’s Remarks at the Media Briefing on COVID‑19; March 11, 2020. Available from: https://www.who.int/dg/speeches/detail/who-directorgeneral-sopening-remarks-at-the-media-briefing-on-covid-19--11‑march‑2020. [Last accessed on 2020 Apr 10]
  4. The Republic of Turkey Ministry of Health COVID-19 Daily Situation Report, June 02, 2021 Available from: URL: https:// covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html. [Last accessed on 2021 June 02]
  5. World Health Organization. Q and A on Coronaviruses. Available from: https://www.who.int/emergencies/diseases/ novel‑coronavirus‑2019/question‑and‑answershub/q‑a‑detail/q‑ a‑coronaviruses#:~:text=symptoms. [Last accessed on 2021 Oct 5]
  6. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of coronavirus 2019 (COVID‑19) pneumonia with other pneumonias. Clin Infect Dis 2020;71:756‑61
  7. Chen H, Ai L, Lu H, Li H. Clinical and imaging features of COVID‑19. Radiol Infect Dis 2020;7:43‑50
  8. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü: COVID-19 (SARS-CoV-2 ENFEKSİYONU) REHBERİ. Bilim Kurulu Çalışması, T.C. Sağlık Bakanlığı 23 Mart, Ankara; 2020
  9. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü: COVID-19 (SARS-CoV-2 ENFEKSİYONU) ERİŞKİN HASTA REHBERİ. Bilim Kurulu Çalışması, T.C. Sağlık Bakanlığı 12 Ekim, Ankara; 2020
  10. Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. J Med Virol 2020;92(9):15251532. [doi: 10.1002/jmv. 25763]
  11. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID‑19: Focus on severity and mortality. Front Public Health 2020;8:152
  12. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev 2009;18:213‑21
  13. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID‑19: The potential role for antifibrotic therapy. Lancet Respir Med 2020;8:807‑15
  14. Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. Sex differences in ca